Mohammadreza Ardalan1, Ali Ghafari2, Fatemeh Hamzavi3, Hamid Nasri4, Behrooz Baradaran5, Jafar Majidi5, Behrooz Nikbin6. 1. DrugApplied Research and 2Chronic kidney disease research center, Tabriz University of Medical Sciences.Tabriz, Iran. ; 2. Department of Nephrology, Urmia University of medical sciences, Urmia, Iran. 3. ; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Science, Isfahan, Iran. 5. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Immunogenetic research center, Department of Immunology, Tehran University of Medical Science, Tehran, Iran.
Abstract
BACKGROUND: Idiopathic Membranous Nephropathy (iMN) is the most common cause of nephrotic syndrome in adults. Approximately one third of patients with iMN progress to end-stage renal disease. Anti-phospholipase A2-receptor (anti-PLA2R) antibodies are present in patients with iMN and appear to play a role in the pathogenesis of iMN. OBJECTIVES: In this study, we explored the prevalence of anti-PLA2R antibodies in a cohort of patients with iMN in Iran. We also sought to determine circulating levels of anti-secretory PLA2 (anti-sPLA2) antibodies in those with anti-PLA2R antibodies. PATIENTS AND METHODS: Using an indirect immunofluorescence assay, we measured anti-PLA2R antibodies in a group of patients with iMN in Iran. The serum levels of anti-sPLA2 antibodies were also measured in those with positive results for anti-PLA2R antibodies. RESULTS: We studied 23 patients with iMN (M/F 12/11, 34±9.8 year), two patients with secondary MN and five patients with the nephrotic syndrome of other causes.Anti-PLA2R antibodies were detected in 17/23 (74%) of patients with iMN, but not in those with secondary MN or other forms of primary glomerular diseases. We found no correlation between anti-PLA2R antibody titer and the degree of proteinuria. We found high titers of anti-sPLA2 antibodies in a subset of patients with high levels of anti-PLA2R antibodies. CONCLUSIONS: Anti-PLA2R antibodies are specific for iMN. Proteinuria may also reflect glomerular structural damage rather than immunological activity of the disease. The preliminary idea of any presumptive role of anti-sPLA2antibodies in iMN needs further investigation.
BACKGROUND:Idiopathic Membranous Nephropathy (iMN) is the most common cause of nephrotic syndrome in adults. Approximately one third of patients with iMN progress to end-stage renal disease. Anti-phospholipase A2-receptor (anti-PLA2R) antibodies are present in patients with iMN and appear to play a role in the pathogenesis of iMN. OBJECTIVES: In this study, we explored the prevalence of anti-PLA2R antibodies in a cohort of patients with iMN in Iran. We also sought to determine circulating levels of anti-secretory PLA2 (anti-sPLA2) antibodies in those with anti-PLA2R antibodies. PATIENTS AND METHODS: Using an indirect immunofluorescence assay, we measured anti-PLA2R antibodies in a group of patients with iMN in Iran. The serum levels of anti-sPLA2 antibodies were also measured in those with positive results for anti-PLA2R antibodies. RESULTS: We studied 23 patients with iMN (M/F 12/11, 34±9.8 year), two patients with secondary MN and five patients with the nephrotic syndrome of other causes.Anti-PLA2R antibodies were detected in 17/23 (74%) of patients with iMN, but not in those with secondary MN or other forms of primary glomerular diseases. We found no correlation between anti-PLA2R antibody titer and the degree of proteinuria. We found high titers of anti-sPLA2 antibodies in a subset of patients with high levels of anti-PLA2R antibodies. CONCLUSIONS: Anti-PLA2R antibodies are specific for iMN. Proteinuria may also reflect glomerular structural damage rather than immunological activity of the disease. The preliminary idea of any presumptive role of anti-sPLA2antibodies in iMN needs further investigation.
Authors: Hanna Debiec; Vincent Guigonis; Béatrice Mougenot; Fabrice Decobert; Jean-Philippe Haymann; Albert Bensman; Georges Deschênes; Pierre M Ronco Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: H Debiec; L Martin; C Jouanneau; G Dautin; L Mesnard; E Rondeau; C Mousson; P Ronco Journal: Am J Transplant Date: 2011-08-09 Impact factor: 8.086
Authors: Horia C Stanescu; Mauricio Arcos-Burgos; Alan Medlar; Detlef Bockenhauer; Anna Kottgen; Liviu Dragomirescu; Catalin Voinescu; Naina Patel; Kerra Pearce; Mike Hubank; Henry A F Stephens; Valerie Laundy; Sandosh Padmanabhan; Anna Zawadzka; Julia M Hofstra; Marieke J H Coenen; Martin den Heijer; Lambertus A L M Kiemeney; Delphine Bacq-Daian; Benedicte Stengel; Stephen H Powis; Paul Brenchley; John Feehally; Andrew J Rees; Hanna Debiec; Jack F M Wetzels; Pierre Ronco; Peter W Mathieson; Robert Kleta Journal: N Engl J Med Date: 2011-02-17 Impact factor: 91.245
Authors: Julia M Hofstra; Laurence H Beck; David M Beck; Jack F Wetzels; David J Salant Journal: Clin J Am Soc Nephrol Date: 2011-04-07 Impact factor: 8.237
Authors: Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant Journal: N Engl J Med Date: 2009-07-02 Impact factor: 91.245